Pfizer Inc. said Monday that it has asked the U.S. Food and Drug Administration to approve the emergency use of an updated booster shot that targets several versions of the Omicron variant.
Animal studies show that the new mRNA vaccine produces an immune response against both BA.4 and BA.5 subvariants, with clinical trials set to begin this month, the company said in a news release announcing the application.
“The agility of the mRNA platform, together with extensive clinical experience with the Pfizer-BioNTech COVID-19 Vaccine, has allowed us to develop, test and manufacture updated, high-quality vaccines that align to circulating strains with unprecedented speed,” said Pfizer Chairman and CEO Albert Bourla.
RELATED: CDC Eases COVID Social Distancing Guidance
“Having rapidly scaled up production, we are positioned to immediately begin distribution of the bivalent Omicron BA.4/BA.5 boosters, if authorized, to help protect individuals and families as we prepare for potential fall and winter surges,” he said in the release.
The BA.5 subvariant accounts for nearly 90% of new U.S. COVID cases, according to the U.S. Centers for Disease Control and Prevention.
The FDA plans to review the data in September. If authorized, the vaccine can be distributed immediately, NBC News reported.
Harvard epidemiologist Bill Hanage told NBC News that the turnaround time for this new vaccine was “remarkably quick.”
It usually takes years for vaccines to be developed and distributed, and the latest Omicron subvariants only began spreading in the United States widely in early June.
You May Also Like
The new vaccine will be “important,” especially for
